Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

Recent & Breaking News (OTCPK:TRPXY)

Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements

PR Newswire February 27, 2020

Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements

PR Newswire February 6, 2020

Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering

PR Newswire December 4, 2019

Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

PR Newswire December 2, 2019

Therapix Biosciences Announces Receipt of Notice of Delisting From Nasdaq and Intention to Appeal

PR Newswire November 20, 2019

Therapix Biosciences Enters Into MOU for Business Combination With Heavenly Rx, Ltd.

PR Newswire November 18, 2019

Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

PR Newswire November 13, 2019

Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

PR Newswire November 7, 2019

Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

PR Newswire October 15, 2019

Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

PR Newswire October 10, 2019

Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

PR Newswire August 27, 2019

Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide(TM)), a Non-Opiate Based Pain Management Supplement

PR Newswire July 31, 2019

Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million

PR Newswire July 23, 2019

Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data

PR Newswire July 5, 2019

Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program

PR Newswire June 18, 2019

Therapix Biosciences Issues Shareholder Update Letter

PR Newswire May 29, 2019

Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance

PR Newswire May 23, 2019

Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering

PR Newswire March 28, 2019

Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor

PR Newswire March 19, 2019

Therapix Biosciences Terminates FSD Acquisition Letter of Intent

PR Newswire December 21, 2018